Cognition Therapeutics shares rise 3.25% premarket after Newron Pharmaceuticals' positive H1 2025 results and business update.

Cognition Therapeutics, Inc. rose 3.25% in premarket trading. The company's stock price increase may be attributed to the positive news from Newron Pharmaceuticals S.p.A., which announced regulatory approval for its pivotal Phase III ENIGMA-TRS program with evenamide as a potential treatment for treatment-resistant schizophrenia. Additionally, Newron Pharmaceuticals reported significant improvements in key efficacy measures for evenamide, which could indicate a positive outlook for the biopharmaceutical sector, potentially influencing Cognition Therapeutics' stock performance.